SEC Form 4 · accession 0001209191-15-031443
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Apr 1, 2015
Accepted (ET)
Apr 2, 2015 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 1, 2015 | M | 1,300 | $17.16 | A | 387,584 | D | |
| Common Stock | Apr 1, 2015 | M | 10,400 | $35.64 | A | 397,984 | D | |
| Common StockF2,F3 | Apr 1, 2015 | S | 1,607 | $114.52 | D | 396,377 | D | |
| Common StockF3,F4 | Apr 1, 2015 | S | 3,800 | $115.54 | D | 392,577 | D | |
| Common StockF3,F5 | Apr 1, 2015 | S | 6,293 | $116.41 | D | 386,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common StockF6 | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $17.16 | Apr 1, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 20,000 | D |
| Stock Option (right to buy)F7 | $35.64 | Apr 1, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 448,000 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $114.52 (range $114.02 to $114.91).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $115.54 (range $115.04 to $116.03).
- F5Open market sales reported on this line occurred at a weighted average price of $116.41 (range $116.12 to $116.66).
- F6Common stock held in grantor retained annuity trusts.
- F7Fully vested.